TU Dublin Secures Nine New Commercialisation-Focused Awards in 2025, Marking a Major Surge in Research Impact
.jpg)
TU Dublin Innovation secures €3 million boost for commercial research in 2025
TU Dublin Innovation has announced a major surge in commercially focused research activity valued at approximately €3 million, securing five Enterprise Ireland Commercialisation Fund (CF) awards in 2025, significantly exceeding its annual target of three. The achievement marks a dramatic increase from 2024, when TU Dublin secured just one CF award, and signals a strong return to the university’s baseline performance over the past two years.
This milestone reflects a substantial investment of time, expertise and collaboration across TU Dublin’s Innovation Office, case managers and research community. It also positions the university strongly for further growth in 2026, with a healthy pipeline already underway. One Proof of Concept (PoC) application has already been submitted, a second is in development, and additional opportunities are actively being explored.
The five Enterprise Ireland awards include two full Commercialisation Fund projects and three Proof of Concept awards. As seen in 2024, both full CF projects secured significant funding, reinforcing TU Dublin’s focus on high-value, high-impact research with strong commercial potential.
The SIMIR project, awarded €721,533 and led by Dr Brian Vaughan at TU Dublin in collaboration with the Royal College of Surgeons in Ireland, is developing an immersive digital simulation platform designed to prepare medical trainees for real clinical environments. The platform combines clinical decision-making with essential soft skills, including communication, teamwork and situational awareness.
Led by Dr Steven Davy at TU Dublin, the LiteStream project, awarded €653,472, is creating a next-generation telemedicine solution that uses AI-driven visual analysis and advanced video compression to help clinicians identify key patient cues during remote consultations, even in low-bandwidth environments.
Anastasia Negru, Commercialisation Lead, LiteStream, commented that:
‘We're tackling a €432 billion market with technology that solves three critical problems: doctors missing visual cues in remote consultations, bandwidth barriers in rural areas, and overwhelming documentation burden. The Enterprise Ireland Commercialisation Fund gives us the resources to conduct trials with clinical partners across Ireland, Sweden, Spain, the US and beyond and prove that Irish innovation can lead the global healthcare AI revolution.’
In addition to its Enterprise Ireland success, TU Dublin has also secured four ARC Hub for ICT Proof of Concept awards, bringing the total number of new commercialisation-focused projects funded in 2025 to nine.
.jpg)
Dr Paul Maguire, Head of Innovation and Knowledge Transfer at TU Dublin, commented
‘These awards mark a pivotal moment for TU Dublin Innovation, reflecting the determination and expertise of our researchers and innovation office team. We are building momentum at a remarkable pace, and the strength of our 2026 pipeline shows that this is only the beginning. Our university is firmly positioning itself as a leader in translating high impact research into real world commercial and societal value.’
These achievements underline TU Dublin’s growing reputation as a leader in research translation, innovation and industry engagement, with a clear focus on turning breakthrough ideas into real-world solutions that deliver commercial and societal impact.
TU Dublin Innovation is co-funded by the Government of Ireland and the European Union through the ERDF Southern, Eastern & Midland Regional Programme 2021-27.